Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 19/20 | 0.51 |
| ▸ | CCND1 | P24385 | 12/20 | 0.50 |
| ▸ | CDK6 | Q00534 | 11/20 | 0.50 |
| ▸ | CDK4 | P11802 | 8/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 7/20 | 0.50 |
| ▸ | CDK9 | P50750 | 7/20 | 0.50 |
| ▸ | CCND3 | P30281 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30804785 | 0.91 | CDK2 (0.53) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL27061762 | 0.91 | CDK2 (0.53) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL27061753 | 0.90 | CDK2 (0.55) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL27061760 | 0.88 | CDK2 (0.52) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL27061977 | 0.87 | CDK2 (0.56) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL30804788 | 0.87 | CDK2 (0.49) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL27061913 | 0.87 | CDK2 (0.49) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL30726224 | 0.86 | CDK2 (0.48) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL27033611 | 0.86 | CDK2 (0.48) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL27061975 | 0.85 | CDK2 (0.47) | CDK2CCNE1CCND1CDK6CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024020380-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |